Product Use Citations
-
Michael DR, et al. The Phosphoinositide 3-Kinase Signaling Pathway is Involved in the Control of Modified Low-Density Lipoprotein Uptake by Human Macrophages.
Lipids. 2015, 50(3):253-60.
-
Stewart H, et al. A novel method for the measurement of hepatitis C virus infectious titres using the IncuCyte ZOOM and its application to antiviral screening.
J Virol Methods. 2015, 10.1016/j.jviromet.2015.03.009.
Daclatasvir (BMS-790052) purchased from Selleck.
-
Basu D, et al. Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.
Neuro Oncol. 2016, 18(4):528-37.
Omipalisib (GSK2126458, GSK458) purchased from Selleck.
-
Booth L, et al. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Oncotarget. 2016, 7(15):19620-30.
Copanlisib (BAY 80-6946) , Amuvatinib (MP-470) purchased from Selleck.
-
Costa-Cabral S, et al. CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.
PLoS One. 2016, 11(2):e0149099.
-
Katsha A, et al. Activation of EIF4E by Aurora kinase A depicts a novel druggable axis in everolimus resistant cancer cells.
Clin Cancer Res. 2017, clincanres.2141.2016.
Alisertib (MLN8237) , Everolimus (RAD001) purchased from Selleck.
-
Jan WC, et al. Phosphoinositide 3-Kinase Is Involved in Mediating the Anti-inflammation Effects of Vasopressin.
Inflammation. 2017, 40(2):435-441.
AS-252424 , PIK-75 HCl purchased from Selleck.
-
Gibot L, et al. Cell-based approach for 3D reconstruction of lymphatic capillaries in vitro reveals distinct functions of HGF and VEGF-C in lymphangiogenesis.
Biomaterials. 2016, 78:129-39.
SU11274 purchased from Selleck.
-
Chen QY, et al. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Oncotarget. 2016, 7(17):24510-26.
SU11274 purchased from Selleck.
-
Wiegmans AP, et al. RAD51 inhibition in triple negative breast cancer cells is challenged by compensatory survival signaling and requires rational combination therapy.
Oncotarget. 2016, 7(37):60087-60100.
BIX 02189 , GSK1904529A and GSK2334470 purchased from Selleck.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- 152
- 153
- 154
- 155
- 156
- 157
- 158
- 159
- 160
- 161
- 162
- 163
- 164
- 165
- 166
- 167
- 168
- 169
- 170
- 171
- 172
- 173
- 174
AllPage:
Page:
